



**SINGAPORE INSTITUTE OF ADVANCED MEDICINE HOLDINGS LTD.**  
(Incorporated in the Republic of Singapore on 24 November 2011)  
(Company Registration Number: 201134046D)

**RESULTS OF ANNUAL GENERAL MEETING**

Pursuant to Rule 704(15) of the Listing Manual Section B: Rules of Catalist of the Singapore Exchange Securities Trading Limited (“**Catalist Rules**”), the Board of Directors (“**Board**”) of Singapore Institute of Advanced Medicine Holdings Ltd. (the “**Company**”) wishes to announce that, at the annual general meeting of the Company held on 27 December 2024 (“**AGM**”), all resolutions relating to the matters set out in the notice of AGM dated 12 December 2024, were duly passed by the shareholders of the Company at the AGM by way of poll.

The information as required under Rule 704(15) of the Catalist Rules is as set out below:

(a) **Breakdown of all valid votes cast at the AGM:**

| Resolution number and details  | Total number of shares represented by votes for and against the relevant resolution | For              |   | Against          |   |
|--|---|------------------|---|------------------|---|
|  |   | Number of shares | As a percentage of total number of votes for and against the resolution (%) | Number of shares | As a percentage of total number of votes for and against the resolution (%) |
| <b>Resolution 1:</b><br>To receive and adopt the Directors’ Statement and Audited Financial Statements for the financial year ended 30 June 2024 together with the Independent Auditors’ Report thereon. | 719,726,619   | 719,726,619      | 100   | 0                | 0   |
| <b>Resolution 2:</b><br>To approve the payment of Directors’ Fees of S\$88,334 for the financial year ended 30 June 2024.  | 719,726,619   | 717,886,869      | 99.74   | 1,839,750        | 0.26  |

| Resolution number and details   | Total number of shares represented by votes for and against the relevant resolution | For              |   | Against          |   |
|---|---|------------------|---|------------------|---|
|   |   | Number of shares | As a percentage of total number of votes for and against the resolution (%) | Number of shares | As a percentage of total number of votes for and against the resolution (%) |
| <p><b>Resolution 3:</b></p> <p>To approve the payment of Directors' Fees of S\$205,348 for the financial year ending 30 June 2025, to be paid half-yearly in arrears.</p>   | 719,726,619   | 717,886,869      | 99.74   | 1,839,750        | 0.26  |
| <p><b>Resolution 4:</b></p> <p>To re-elect Mr Yeo Seng Lye Paul as a Director of the Company.</p>   | 719,726,619   | 719,716,619      | 100   | 10,000           | 0   |
| <p><b>Resolution 5:</b></p> <p>To re-elect Dato' Lee Kok Chuan as a Director of the Company.</p>  | 719,726,619   | 719,676,619      | 99.99   | 50,000           | 0.01  |
| <p><b>Resolution 6:</b></p> <p>To re-elect Mr Gurdip Singh S/O Boor Singh as a Director of the Company.</p>   | 719,726,619   | 719,676,619      | 99.99   | 50,000           | 0.01  |
| <p><b>Resolution 7:</b></p> <p>To appoint Messrs Foo Kon Tan LLP as Auditors of the Company in place of the retiring Auditors, Messrs PricewaterhouseCoopers LLP, to hold office until conclusion of the next AGM of the Company and to authorise the Directors of the Company to fix its remuneration.</p> | 719,726,619   | 719,726,619      | 100   | 0                | 0   |
| <p><b>Resolution 8:</b></p> <p>To authorise the Directors to allot and issue shares and convertible securities.</p>   | 719,726,619   | 717,876,869      | 99.74   | 1,849,750        | 0.26  |

(b) **Re-election of Directors – Ordinary Resolutions 4, 5 and 6**

Mr Yeo Seng Lye Paul, Dato' Lee Kok Chuan and Mr Gurdip Singh S/O Boor Singh were re-elected as Directors of the Company at the AGM.

- (i) Mr Yeo Seng Lye will continue to serve as the Executive Director and Chief Operating Officer of the Company.
- (ii) Dato' Lee Kok Chuan, a Non-Executive and Non-Independent Director of the Company, will continue to serve as a Member of the Audit Committee of the Company. He is considered non-independent by the Board for the purpose of Rule 704(7) of the Catalist Rules.
- (iii) Mr Gurdip Singh S/O Boor Singh, an Independent Director of the Company, will continue to serve as the Chairman of the Audit Committee and a Member of the Remuneration Committee of the Company. He is considered independent by the Board for the purpose of Rule 704(7) of the Catalist Rules.
- (iv) On 12 December 2024, the Company announced the formation of a Strategic Review Committee ("SRC") by the Board, of which Dato' Lee Kok Chuan and Mr Gurdip Singh S/O Boor Singh, are Members of the SRC, and they will also continue to serve as Members of the SRC of the Company.

(c) **Details of parties who are required to abstain from voting on any resolution(s)**

No party is required to abstain from voting on the resolutions.

(d) **Name of firm appointed as scrutineer**

CNP Business Advisory Pte. Ltd. was appointed as scrutineer for the AGM.

BY ORDER OF THE BOARD

Dr Djeng Shih Kien  
Executive Director and Chief Executive Officer  
27 December 2024

---

Singapore Institute of Advanced Medicine Holdings Ltd. (the "**Company**") was listed on Catalist of the Singapore Exchange Securities Trading Limited ("**SGX-ST**") on 16 February 2024. The initial public offering of the Company was sponsored by PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**").

This announcement has been reviewed by the Sponsor. It has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this document, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms. Ng Shi Qing, 16 Collyer Quay, #10-00 Collyer Quay Centre, Singapore 049318, sponsorship@ppcf.com.sg.